Deferasirox治疗铁质积聚疗效怎么样？

It is an oral iron chelator used to treat iron overload caused by blood transfusions in patients with certain hematological diseases.

In 2005, Deferasirox was approved by the FDA for the treatment of iron overload caused by blood transfusion in patients with chronic anemia 2 years and older during treatment. So, how effective is Deferasirox in treating iron accumulation?

Analyze the therapeutic effect of Deferasirox dispersible tablets in the treatment of children with iron overload in β-thalassemia major.

Forty-six children with iron overload caused by β-thalassemia major who were treated from October 2015 to October 2017 were selected and divided into the Deferasirox group and the deferoxamine group according to the random number table method, with 23 cases in each group. The Deferasirox group was treated with oral Deferasirox, and the deferoxamine group was treated with subcutaneous pump deferoxamine. The disease control effect after 1 year of medication, serum iron (SI), ferritin (SF), brain natriuretic peptide (BNP), troponin I (cTnI) and urinary ferritin (UF) levels before and after medication, liver and heart MRI T2* values ​​before and after medication, and adverse drug reactions were compared between the two groups.

Results: The disease control rate in the Deferasirox group was 100%, which was higher than 78.26% in the deferoxamine group (word 2=5.610, P=0.018); after treatment, the serum SI, SF, BNP and cTnI levels in the Deferasirox group were lower than those in the deferoxamine group, and UF levels, liver and heart MRI The T2 values were all higher than those in the deferoxamine group, and the differences were statistically significant (P<0.05); the incidence of adverse reactions in the Deferasirox group was lower than that in the deferoxamine group (P<0.05).

Conclusion: The treatment of iron overload in children with β-thalassemia major has better disease control effect than deferoxamine. It can effectively reduce serum SI, SF, BNP and cTnI levels, reduce the load of iron overload on the liver and heart, and the drug is safer.